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ABSTRACT 
Due to limited available information on the occurrence and treatment of uterine cancer, health institutions 
in major countries trend to study some factors and diseases that may relation or plays as predisposing 
factors of the occurrence of uterine cancer and the lack of previous studies on the impact of osteoporosis 
on the incidence of uterine cancer and the rapid spread of uterine cancer in recent years all over the world 
and till know the exact mechanism is not fully clear. This study focused on the following: Possibility of 
osteoporosis as a marker of uterine cancer by studying the relationship between osteoporosis and uterine 
cancer through a biochemical and hormonal parameters responsible for osteoporosis and its effect on 
uterus  and  possibility  of  malignant  changes.  The  study  included  collection  of  samples  attending  the 
Hospitals in Mosul, from 82 women had no uterine cancer and divided to two groups (44 healthy women 
and 38 women diagnosed as osteoporosis only) and 101 women with uterine cancer (43 with uterine 
cancer  only  and  58  women  are  associated  osteoporosis  with  uterine  cancer  dose  not  received  any 
treatment for their condition). Each patient was evaluated clinically and by a biochemical laboratory 
tests,  which  include  phosphorus,  calcium,  vitamin  D3,  alkaline  phosphatase  ALP,  estrogen  and 
progesterone in serum by using commercial kits. The results showed the osteoporosis may increases the 
incidence of uterine cancer. Novel of this research showed that Osteoporosis is a new risk factor for 
uterine cancer. Accordingly, women should pay attention for her bone health and early diagnosis and 
treatment of osteoporosis to prevent and reduce the risk of uterine cancer. 
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1. INTRODUCTION 
Uterine cancer is the third most common malignant 
tumors in women and the incidence of uterine cancer has 
doubled over the last six years. Where more than 40% of 
malignant tumors in women is a cancer of the uterus. It is 
the third most common cancer in females after breast and 
ovarian cancer and carry a high death rate (Yang et al., 
2011). Although a large number of women affected, the 
pathophysiological mechanisms is still largely unknown 
(Haughian et al., 2009). 
Osteoporosis is common in older people and in post-
menopausal  women.  It  is  a  growing  health  problem 
worldwide  and  women  in  pre-menopausal  stage  are  at 
high  risk  the  disease  after  the  next  twenty  years.  The 
major  determinant  of  bone  strength  and  the  risk  of 
osteoporosis  is  Bone  Mineral  Density  (BMD),  which 
increases the  chance of  fractures is  due to  lack of  the 
hormone  estrogen,  which  helps  to  integrate  calcium  in 
the bones, in addition to mineral deficiency responsible 
for  bone  density  (Kamienski  et  al.,  2011).  To  build 
strong bones it needs calcium, phosphorus and vitamin D 
(Lips and Schoor, 2011; Trummer et al., 2012). Vitamin 
D may play a protective role in human cancer. There is 
need for further studies to verify that the protective effect 
of  calcium  and  vitamin  D  can  be  expanded  to  uterine 
cancer  (Byers,  2010).  The  aim  of  this  study  is  the 
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by  studying  the  relationship  between  osteoporosis  and 
uterine  cancer  through  a  biochemical  and  hormonal 
parameters responsible for osteoporosis and its effect on 
uterus  and possibility of malignant changes and this is 
done for the first time. 
2. MATERIALS AND METHODS 
The  study  included  collection  of  samples  attending 
the Hospitals in Mosul, from 82 women had no uterine 
cancer and divided to two groups (44 healthy women and 
38  women  diagnosed  as  osteoporosis  only)  and  101 
women with uterine cancer (43 with uterine cancer only 
and 58 women are associated osteoporosis with uterine 
cancer  dose  not  received  any  treatment  for  their 
condition). Each patient was evaluated clinically and by 
a biochemical laboratory tests, which include estrogen, 
progesterone,  vitamin  D3,  calcium,  phosphorus  and 
alkaline phosphatase ALP in serum by using commercial 
kits (Bio Merieux Vitek, Inc., UAS). 
The statistical methods used to analysis the data include 
mean, standard deviation, minimum and maximum, while 
T-test was used to compare between total control and total 
patients according to the occupation at p≤0.05 and p≤0.001 
(Kirkpatrick and Feeney, 2012). 
3. RESULTS 
The result in Table 1 showed a significant differs at p 
= 0.001 of biochemical parameters (Vit. D3 and P) on 
women uterine cancer compared with control group. 
Result in Table 2 showed a significant differs at p = 
0.05,  p  =  0.04,  p  =  0.04,  p  =  0.03  and  p<0.0001  of 
biochemical parameters (Estrogen, Progesterone, Vit. D3, 
P  and  ALP)  on  women  with  uterine  cancer  compared 
with women osteoporosis group. 
Table 3 showed a significant differs at p<0.0001, p = 
0.05 and p<0.001 and p≤0.0001 of biochemical parameters 
(Vit. D3, Ca and ALP) on women with osteoporosis and 
uterine cancer compared with control group. 
 
Table 1. Effect of biochemical parameters on women with uterine cancer and control group 
Biochemical  Woman with Uterine  Control group 
Parameters  Cancer Mean±S.E  Mean±S.E  P values 
Estrogen (pg/mL)  48.04±17.2  38.65±16.4  N 
Progesterone (ng/mL)  0.75±0.3  1.25±0.12  N 
Vit. D3 (µg/L)  29.59±6.6  38.24±14.74***  0.001 
Calcium (mmol/L)  1.27±0.29  1.46±0.21***  0.001 
ALP (U/L)  67.51±10.45  71.09±12.5  N 
***; Significant differences at p = 0.001 
 
Table 2. Effect of biochemical parameters on women with uterine cancer and osteoporosis compared with control group 
Biochemical  Woman with uterine  Woman with 
parameters  cancer mean±S.E  Osteoporosis Mean±S.E  P values 
Estrogen (pg/mL)  48.04±17.2  91.01±10.3*  0.05  
Progesterone (ng/mL)  0.75±0.3  2.41±0.5*  0.04 
Vit. D3 (µg/L)  29.59±6.6  26.6±6.02*  0.04 
Calcium (mmol/L)  2.36±0.16  2.39±0.19  N 
phosphorus (mmol/L)  1.27±0.29  1.39±0.15*  0.03 
ALP (U/L)   67.51±10.45  95.79±21.2***  < 0.0001 
*; Significant differences at p≤0.05, ***; Significant differences at p≤0.001 
 
Table 3.  Effect of biochemical parameters on women with Osteoporosis and uterine cancer compared with control group 
Biochemical  Osteoporosis and uterine  Control group 
Parameters  cancer Mean±S.E  Mean ± S.E  P values 
Estrogen (pg/mL)  24.41±17.2  38.65±16.4  N   
Progesterone (ng/mL)  0.92±0.2  1.25±0.12  N 
Vit. D3 (µg/L)  21.88±11.5  38.24±14.74***  < 0.0001 
Calcium (mmol/L)  2.4±0.26  2.32±0.14*  0.05 
phosphorus (mmol/L)  1.45±0.55  1.46±0.21  N 
ALP (U/L)  113.34±52.08  71.09±12.5***  < 0.001 
*; Significant differences at p≤0.05, *** Significant differences at p≤0.001 Z.A. Monim Al-Jawadi and Z. Mahfoth Al-noaymy / American Journal of Applied Sciences 11 (1): 105-108, 2014 
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Table 4. Effect of biochemical parameters on women with Osteoporosis and uterine cancer compared with osteoporosis group 
Biochemical  Osteoporosis and uterine  Woman with 
Parameters  cancer Mean ± S.E  Osteoporosis Mean ± S.E  P values 
Estrogen (pg/mL)  24.41±17.2  91.01±10.3***  <0.0001 
Progesterone (ng/mL)  0.92±0.2  2.41±0.5*  0.02 
Vit. D3 (µg/L)  21.88±11.5  26.6±6.02*  0.02 
Calcium (mmol/L)  2.4±0.26  2.39±0.19  N 
Phosphorus (mmol/L)  1.45±0.55  1.39±0.15  N 
ALP (U/L)  113.34±52.08  95.79±21.2*  0.05 
*; Significant differences at p≤0.05, *** Significant differences at p≤0.001 
 
Result  in  Table  4  showed  a  significant  differs  at 
p<0.0001,  p  =  0.02  and  p  =  0.02  and  p  =  0.05  of 
biochemical parameters (Estrogen, Progesterone, Vit. D3 
and  ALP)  on  women  with  Osteoporosis  and  uterine 
cancer compared with women osteoporosis group. 
4. DISCUSSION 
Uterine  cancer  is  very  common  in  female  and  like 
most malignant tumors there is no apparent reason for its 
occurrence  but  it  is  certain  that  hormones  plays 
important  factor  affecting  this  organ.  Through  the 
relationship  between  imbalance  female  hormones, 
especially  estrogen  effect  on  bone  density  lead  to 
osteoporosis and its one of the risk  factors for uterine 
cancer as seen in Table 2 and 4. The exoskeleton of the 
body and therefore they need maintenance a permanent 
support where they are rebuilt continuously through the 
stages of life, the bone cells begin construction and reach 
a peak in the age of twenty, but after the third and fourth 
decade over widening between bone cells and be the loss 
is more than building at the proximity of the fifth decade, 
the  loss  rate  up  to  more  than  25%  of  the  skeleton. 
Osteoporosis  is  a  silent  disease,  where  bone  density 
gradually.  The  study  showed  that  low  serum  levels  of 
vitamin D3 as seen in Table 2, have effect on osteoporosis 
and this consistent with other study (Watts et al., 2012). 
As  well  as  lower  serum  vitamin  D3  in  women  with 
osteoporosis  and  uterine  cancer,  as  shown  in  Table  3 
and 4, probably for the same reason. It is well known 
that  vitamin  D3  regulate  the  level  of  phosphorus  and 
calcium in the blood by participating in the process of 
mineral  metabolism  and  bone  growth  and  this  was 
confirmed by the results in (Table 1-3). In the absence 
of  vitamin  D3,  calcium  and  phosphorus  does  not 
absorbed  with  high  efficiency  (Calvo  and  Uribarri, 
2013; Yousef et al., 2013) and thus withdrawn from the 
bones into the blood and this may not seen clearly in the 
blood and this is what shown in the (Table 1-4) and as a 
result increase the level of the enzyme alkaline phosphatase 
which  is  one  of  the  most  important  clinical  biochemical 
indicators  of  osteoporosis  (Gonzlez-Perez  et  al.,    2011). 
This study showed that osteoporosis may increases the 
incidence of uterine cancer. Accordingly, women should 
pay attention for her bone health and early diagnosis and 
treatment of osteoporosis to prevent and reduce the risk 
of uterine cancer. 
5. CONCLUSION 
Novel of this research showed that Osteoporosis is a 
new risk factor for uterine cancer. Accordingly, women 
should  pay  attention  for  her  bone  health  and  early 
diagnosis and treatment of osteoporosis to prevent and 
reduce the risk of uterine cancer.  
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